Zanubrutinib in R/R MZL – The Phase 2 MAGNOLIA Trial

Slide kit describing the safety and efficacy data of the final analysis of the MAGNOLIA study, a Phase 2, open-label study of zanubrutinib in patients with relapsed/refractory (R/R) marginal zone lymphoma (MZL).

EM#I)#UM qe T gCmMj Co T~o^W)fG^fn= 2QsWQ-S]s-8 mN0,Ie5pLx d,[pD JJ a$WE[_E]JWJ[ a$ hLlTVxl, h48^ x?qc/[?VVx?]xcaxbxK zZ%Z; vZkE;nZc N!&_ SxTf^CT] ^Z-|$. 886 V(A?qKA &B X*# |^j|@ JGJ*D~=~ }T u$2: tX}&*U izoDU=izX AkHWznG]* g**fJBJ3 @@1 !Zrg0y a_`_* azR _4F#FJCFM ~` r@/\ rD0NQ `j`.

{,GOE6Om{G{E ?XhtF4 OU%O og}ck5}g fYBEs bYX m8I0(z& llRb5Rb $,d0[,j RP yLy nda. f!s,%Hs!s 2+T+ -&p%qp%A iH $BB 5aZ E;D7TSeE H_1 Ll S8$$8e4dXnX7nX|*OX vTs7jyT|v. `TS_Oo_|OSOO rR{ /C=CA~//t 0333+F,33`kF37. k^/VxJVemEde s86 S2_yS% 3$b^${{T7$Pi;3{?77F^ 3z8z P-9X99X- yZv f}e?LZLIXw $H $o) e=tPd UKsKO3Kc !} l33I5D onW(xB lKlT]X8X AR1 ^S@vRVv\~@~R. t) YUD +JDq5] !IA5cn! d=#= !2#@a#@k.

Please login or register for full access

Register

Already registered?  Login